Condition: Solid Advanced Tumor · Lymphoma · NSCLC (Non-small Cell Lung Cancer) · Sponsor: OSE Immunotherapeutics
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.
This description comes directly from the study's public registry record.
Sylvie Jouve, PhD · +33 631 654 710 · sylvie.jouve@ose-immuno.com
Silvia Comis, MD · +349 347 1495656 · silvia.comis@ose-immuno.com
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| Antwerp University Hospital | Edegem, Belgium | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hopital Saint Joseph | Paris, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Completed |
| Institut de Cancerologie de l'Ouest | Saint-Herblain, France | Recruiting |
| Oncopole | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| University Hospital A Coruña Biomedical Research Institute (INIBIC) | A Coruña, Spain | Recruiting |
| Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI) | Girona, Spain | Recruiting |
| Hospital Regional Universitario de Málaga | Málaga, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05751798